Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 9
Submit an article Journal homepage
428
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes

Stephan R. BohlDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
,
Anna DolnikDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
,
Thomas JensenMedical Prognosis Institute (MPI), Hørsholm, Denmark;
,
Katharina M. LangDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
,
Björn HackansonDepartment of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany
,
Verena I. GaidzikDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
,
Peter PaschkaDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
,
Steen KnudsenMedical Prognosis Institute (MPI), Hørsholm, Denmark;
,
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
,
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
,
Rainer ClausDepartment of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany
,
Michael LübbertDepartment of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany
&
Lars BullingerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; Correspondence[email protected]
 show all
Pages 2264-2267 | Received 28 Sep 2016, Accepted 18 Jan 2017, Published online: 13 Feb 2017

References

  • Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136–1152.
  • Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–2036.
  • Ettou S, Audureau E, Humbrecht C, et al. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia. 2012;26:2297–2299.
  • Bullinger L, Ehrich M, Dohner K, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood. 2010;115:636–642.
  • Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013;27:1803–1812.
  • Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393–401.
  • Rucker FG, Lang KM, Futterer M, et al. Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. Epigenetics. 2016;11:517–525.
  • Chuang HY, Lee E, Liu YT, et al. Network-based classification of breast cancer metastasis. Mol Syst Biol. 2007;3:140
  • Lindner DJ, Wu Y, Haney R, et al. Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-aza-deoxycytidine suppresses angiogenesis. Matrix Biol. 2013;32:123–132.
  • Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci USA. 2008;105:6584–6589.
  • Guo XL, Pan L, Zhang XJ, et al. Expression and mutation analysis of genes that encode the Myc antagonists Mad1, Mxi1 and Rox in acute leukaemia. Leuk Lymphoma. 2007;48:1200–1207.
  • Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94:131–134.
  • Hebestreit K, Grottrup S, Emden D, et al. Leukemia gene atlas-a public platform for integrative exploration of genome-wide molecular data. PLoS One. 2012;7:e39148.
  • Liu S, Wu LC, Pang J, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17:333–347.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.